Starna extends range of CRMs to cover Far UV to NIR spectral region - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Starna extends range of CRMs to cover Far UV to NIR spectral region

Starna Scientific’s Reference Material and Calibration manufacturing laboratory has extended the Starna range of Certified Reference Materials (CRMs), providing the most comprehensive range of UV/Visible/NIR Materials currently available under the scope of ISO Guide 34 + ISO/IEC 17025 accreditation for Reference Material producers.

"We now hold a unique position in the production of CRMs for wavelength and Transmittance scales, certified in accordance with ISO Guide 34 and ISO/IEC 17025, for the complete Far UV to NIR spectral region (190 – 2850 nm)," explained Keith Hulme, Starna's Managing Director.

The Starna® Lifetime Guarantee is offered on all Starna® manufactured Certified Reference Materials (CRMs). The guarantee provides for a free of charge replacement should the assigned values move outside the expanded uncertainty budget within the recertification period of two years, subject to conditions of use/care and recertification by Starna at least every two years.

The CRMs are essential for ISO/IEC accredited laboratories, pharmaceutical QA/QC or metrology departments enabling the provision of Operational Qualification (OQ) and Performance Qualification (PQ) of UV/Visible/NIR instrumentation using 'Industry Standard' protocols.

Starna is the only Reference Material producer accredited to both ISO Guide 34 and ISO/IEC 17025 in the UV/Visible/NIR spectral range. The CRMs the company now provide extend the scope of available materials for spectral range, band width and photometric linearity.

Visit www.starna.com, email sales@starna.com or call + 44 (0) 20 8501 5550 for more information.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
FindPharma Custom Search

Click here